Nova Eye Lifts FY26 Sales Guidance to US$22-23M After Record USA Sales in April
Nova Eye Medical upgrades FY26 sales guidance after record April performance
Nova Eye Medical has upgraded its FY26 sales guidance (excluding China) to US$22–23 million, up from the previous range of US$21–22 million, following a record monthly sales performance in the USA during April 2026. The upgrade comes as trailing twelve-month sales (excluding China) reached US$21.6 million at 30 April 2026, representing 27% growth on the prior comparative period.
April 2026 set a new monthly sales record in the USA, exceeding the record established just one month earlier in March 2026. Group trailing twelve-month sales reached US$22.8 million, up 26% on the prior comparative period. With two months of FY26 remaining, management has raised guidance mid-quarter, signalling confidence in sustained demand momentum rather than isolated performance.
The upgraded guidance translates to A$31.4–32.8 million assuming an FX rate of AUD1.00 = USD0.70 in the final quarter. Trading conditions across the U.S. interventional glaucoma sector remain supportive, with management noting continued momentum as the financial year approaches completion.
When big ASX news breaks, our subscribers know first
What is interventional glaucoma surgery and why does it matter for investors?
Glaucoma is a leading cause of irreversible blindness worldwide, traditionally managed through daily eye drops or invasive surgical procedures. Interventional glaucoma represents a category of minimally invasive surgical approaches designed to reduce patient reliance on daily medications by restoring the eye’s natural drainage pathways.
Nova Eye Medical’s iTrack Advance device is a canaloplasty tool that enables surgeons to restore the eye’s natural outflow pathway, lowering intraocular pressure without the use of permanent implants or stents. The company’s Molteno3 glaucoma drainage device addresses severe glaucoma cases where tissue-sparing approaches may not be sufficient.
The structural market opportunity is significant. Approximately 32 million cataract procedures are performed annually, with around 1 in 5 patients also presenting with glaucoma. This creates a large addressable patient population for interventional glaucoma procedures that can be combined with cataract surgery. Nova Eye Medical competes in this market with tissue-sparing, stent-free approaches that are gaining clinical preference among ophthalmic surgeons seeking alternatives to permanent implants.
USA sales momentum driving group performance
The USA market delivered US$17.8 million in trailing twelve-month sales at 30 April 2026, up 28% on the prior comparative period. As Nova Eye Medical’s largest direct market, the USA represents the primary driver of group performance, accounting for the majority of revenue (excluding China).
Sales representative productivity remains strong, with each U.S. sales representative delivering approximately US$1.6 million in annualised revenue on a weighted average basis during Q3 FY26. U.S. sales have grown at a compound quarterly rate of approximately 6% over the last six quarters, demonstrating consistent execution across consecutive periods.
Sector conditions in the U.S. remain supportive. The U.S. accounts for approximately 53% of global interventional glaucoma market revenue and is growing at 8% per annum, according to company disclosures. Recent results from listed U.S. interventional glaucoma peers point to sustained end-market demand for canaloplasty and stent-free, tissue-sparing surgical approaches.
| Region | LTM April 2025 (US$’000s) | LTM April 2026 (US$’000s) | Growth |
|---|---|---|---|
| USA | 13,820 | 17,758 | +28% |
| Germany | 1,782 | 1,851 | +4% |
| ROW | 1,464 | 2,038 | +39% |
| Sales (excl. China) | 17,066 | 21,646 | +27% |
Consecutive monthly records in the USA and sustained compound quarterly growth indicate repeatable sales execution rather than lumpy ordering patterns. The company’s direct sales force continues to penetrate the U.S. market, with productivity metrics suggesting efficient capital deployment per sales representative.
Rest of World adds diversification upside
The Rest of World (ROW) segment delivered the fastest percentage growth among regions, reaching US$2.0 million in trailing twelve-month sales at 30 April 2026, up 39% on the prior comparative period. This geographic segment provides diversification away from the core U.S. market and represents an emerging growth opportunity as Nova Eye Medical expands distribution partnerships globally.
Germany, a direct market for the company, grew modestly at 4% to US$1.9 million in trailing twelve-month sales. China contributed US$1.2 million in trailing twelve-month sales, up 11%, but is excluded from guidance due to the distribution structure in that market.
Geographic diversification provides resilience if growth slows in any single market. The ROW segment’s acceleration suggests early-stage market penetration that may offer sustained growth as distribution networks mature and product adoption increases.
Profitability milestone reinforces operating leverage
Nova Eye Medical reported its first positive EBITDA from Operations of US$138,000 for Q3 FY26, as disclosed in the Quarterly Activities and Cashflow Report on 29 April 2026. This profitability milestone occurred alongside accelerating sales growth, demonstrating operating leverage as revenue scales across the existing cost base.
Q3 FY26 Profitability Milestone
Nova Eye Medical achieved its first positive EBITDA from Operations of US$138,000 in Q3 FY26, marking a significant transition to profitability as sales momentum builds across key markets.
The achievement of positive EBITDA from Operations at this revenue scale suggests potential for further margin expansion as fixed costs are absorbed by incremental sales. With U.S. sales representatives delivering approximately US$1.6 million in annualised revenue each on a weighted average basis, the company’s go-to-market model appears to be reaching efficient operating scale.
The transition to profitability while simultaneously accelerating sales growth indicates that the business model can generate cash as it scales, reducing reliance on external capital to fund operations. Further EBITDA progression is expected in Q4 FY26 as the company completes the financial year.
The next major ASX story will hit our subscribers first
Outlook and what to watch next
Nova Eye Medical has reaffirmed upgraded FY26 sales guidance (excluding China) of US$22–23 million, equivalent to A$31.4–32.8 million assuming an FX rate of AUD1.00 = USD0.70 in the last quarter. Two months of FY26 remain (May and June 2026), with management noting continued trading momentum and supportive U.S. market conditions.
The company’s disclosure that April 2026 set a new monthly sales record, exceeding the record established in March 2026, indicates acceleration into the final quarter rather than deceleration. Listed U.S. interventional glaucoma peers continue to report sustained end-market demand for canaloplasty and stent-free approaches, supporting the sector-level growth trajectory.
Upcoming catalysts include:
- FY26 full-year sales result (July 2026)
- Continued U.S. sales rep productivity trends
- Further EBITDA progression in Q4 FY26
The combination of sales momentum, positive EBITDA from Operations, and supportive sector conditions positions Nova Eye Medical for potential further upgrades if the current trajectory holds through May and June 2026. Investors will be watching whether the company can maintain U.S. sales representative productivity at US$1.6 million annualised revenue per rep, and whether the ROW segment’s 39% growth rate can be sustained as distribution networks mature.
Ready to Learn More About Nova Eye Medical’s Interventional Glaucoma Opportunity?
Nova Eye Medical has delivered consecutive monthly sales records in the USA whilst achieving its first positive EBITDA from Operations in Q3 FY26. The company’s iTrack Advance and Molteno3 devices address a substantial market opportunity with approximately 32 million cataract procedures performed annually, of which one in five patients also present with glaucoma.
For detailed project updates, financial reports and strategic analysis, visit the Nova Eye Medical investor centre. Investors can access comprehensive data on sales performance, market penetration and EBITDA progression as the company scales towards sustained profitability.